D. Boral Capital Reaffirms “Buy” Rating for Trevi Therapeutics (NASDAQ:TRVI)

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reaffirmed by equities research analysts at D. Boral Capital in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $19.00 price objective on the stock. D. Boral Capital’s target price would indicate a potential upside of 24.75% from the stock’s current price.

Several other research firms also recently issued reports on TRVI. Morgan Stanley lowered their price objective on Trevi Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Wednesday, January 21st. Needham & Company LLC upped their target price on Trevi Therapeutics from $22.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. Finally, Stifel Nicolaus upped their target price on Trevi Therapeutics from $15.00 to $18.00 and gave the company a “buy” rating in a report on Friday, December 19th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Trevi Therapeutics currently has a consensus rating of “Buy” and an average target price of $21.60.

Trevi Therapeutics Price Performance

Trevi Therapeutics stock opened at $15.23 on Friday. The business has a 50 day moving average of $11.83 and a 200-day moving average of $11.57. Trevi Therapeutics has a 1 year low of $5.38 and a 1 year high of $15.76. The company has a market capitalization of $1.96 billion, a P/E ratio of -47.59 and a beta of 0.99.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Tuesday, March 17th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.04. Equities analysts anticipate that Trevi Therapeutics will post -0.49 EPS for the current year.

Institutional Trading of Trevi Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Diversified Trust Co boosted its holdings in Trevi Therapeutics by 11.9% in the first quarter. Diversified Trust Co now owns 23,477 shares of the company’s stock valued at $280,000 after acquiring an additional 2,493 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Trevi Therapeutics in the fourth quarter valued at approximately $50,000. Seven Fleet Capital Management LP bought a new stake in Trevi Therapeutics in the fourth quarter valued at approximately $89,000. Invesco Ltd. boosted its holdings in Trevi Therapeutics by 3.3% in the fourth quarter. Invesco Ltd. now owns 498,926 shares of the company’s stock valued at $6,247,000 after acquiring an additional 15,856 shares during the last quarter. Finally, KVP Capital Advisors LP bought a new stake in Trevi Therapeutics in the fourth quarter valued at approximately $5,183,000. 95.76% of the stock is currently owned by institutional investors.

Key Stories Impacting Trevi Therapeutics

Here are the key news stories impacting Trevi Therapeutics this week:

• Positive Sentiment: Pricing of an underwritten offering will provide ~ $150M in gross proceeds to fund Haduvio development and extend runway — this reduces near-term cash risk for clinical programs. Read More.
• Positive Sentiment: D. Boral Capital reiterated a “Buy” and set a $19 price target (about mid‑teens upside from the current level), which supports positive analyst sentiment and can attract buyers. Read More.
• Neutral Sentiment: The offering was priced at $13.00 per share for 11.6M shares, with a 30‑day option for an additional 1.74M shares; expected close is on or about April 20, subject to customary conditions. This is procedural but important to completion. Read More.
• Neutral Sentiment: Underwriters include Morgan Stanley, Leerink, Cantor and Stifel — participation by major banks can help execution and distribution of the deal. Read More.
• Negative Sentiment: All shares in the offering are being sold by Trevi, which dilutes existing shareholders and may pressure near-term per‑share metrics. Expect increased share count and potential short‑term selling pressure once shares are issued. Read More.
• Negative Sentiment: Market reaction was immediate: the announcement triggered a sharp intraday selloff in some reports, signaling investor sensitivity to dilution and near‑term capital raises. Expect elevated volatility while the deal closes. Read More.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.